World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 2812968

Number of visits today: 17

Number of downloads: 2063811

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, Sang S, Deng S. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. Molecules 2021;26:6482. [PMID: 34770887 DOI: 10.3390/molecules26216482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]

For:

Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, Sang S, Deng S. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. Molecules 2021;26:6482. [PMID: 34770887 DOI: 10.3390/molecules26216482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]

Number	Citing Articles
1	Du W, Jiang P, Li Q, Wen H, Zheng M, Zhang J, Guo Y, Yang J, Feng W, Ye S, Kamara S, Jiang P, Chen J, Li W, Zhu S, Zhang L. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants. Microbiol Spectr 2023;11:e0356222. [PMID: 36511681 DOI: 10.1128/spectrum.03562-22] [Reference Citation Analysis]
2	Shi J, Du S, Wang R, Gao H, Luo Q, Hou G, Zhou Y, Zhu Z, Wang F. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer (99m)Tc-HP-Ark2: a pilot study. J Transl Med 2023;21:19. [PMID: 36631812 DOI: 10.1186/s12967-022-03865-y] [Reference Citation Analysis]
3	Jia D, Liu H, Zheng S, Yuan D, Sun R, Wang F, Li Y, Li H, Yuan F, Fan Q, Zhao Z. ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors. Mol Pharm 2023;20:427-37. [PMID: 36315025 DOI: 10.1021/acs.molpharmaceut.2c00708] [Reference Citation Analysis]
4	Miladinova D. Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine. Front Mol Biosci 2023;10:1144817. [PMID: 36936995 DOI: 10.3389/fmolb.2023.1144817] [Reference Citation Analysis]
5	Qin X, Guo X, Liu T, Li L, Zhou N, Ma X, Meng X, Liu J, Zhu H, Jia B, Yang Z. High in-vivo stability in preclinical and first-in-human experiments with [(18)F]AlF-RESCA-MIRC213: a (18)F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers. Eur J Nucl Med Mol Imaging 2023;50:302-13. [PMID: 36129493 DOI: 10.1007/s00259-022-05967-7] [Reference Citation Analysis]
6	Zappala F, Higbee-Dempsey E, Jang B, Miller J, Yan L, Minutolo NG, Rosado González GT, Tsourkas A, Ozdemir BA. Rapid, site-specific labeling of "off-the-shelf" and native serum autoantibodies with T cell-redirecting domains. Sci Adv 2022;8:eabn4613. [PMID: 35522741 DOI: 10.1126/sciadv.abn4613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]